NO20002001D0 - Peptides capable of inhibiting the interaction between presenilines and the <beta> -amyloid peptide or its precursor - Google Patents

Peptides capable of inhibiting the interaction between presenilines and the <beta> -amyloid peptide or its precursor

Info

Publication number
NO20002001D0
NO20002001D0 NO20002001A NO20002001A NO20002001D0 NO 20002001 D0 NO20002001 D0 NO 20002001D0 NO 20002001 A NO20002001 A NO 20002001A NO 20002001 A NO20002001 A NO 20002001A NO 20002001 D0 NO20002001 D0 NO 20002001D0
Authority
NO
Norway
Prior art keywords
presenilines
precursor
beta
inhibiting
interaction
Prior art date
Application number
NO20002001A
Other languages
Norwegian (no)
Other versions
NO328908B1 (en
NO20002001L (en
Inventor
Christian Czech
Luc Mercken
Laurent Pradier
Soline Reboul-Becquart
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9713384A external-priority patent/FR2770217B1/en
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20002001D0 publication Critical patent/NO20002001D0/en
Publication of NO20002001L publication Critical patent/NO20002001L/en
Publication of NO328908B1 publication Critical patent/NO328908B1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
NO20002001A 1997-10-24 2000-04-17 In vitro use of a polypeptide capable of inhibiting the interaction between presenilines and APP. NO328908B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9713384A FR2770217B1 (en) 1997-10-24 1997-10-24 PEPTIDES CAPABLE OF INHIBITING THE INTERACTION BETWEEN PRESENILINS AND THE PRECURSOR OF B-AMYLOID PEPTIDE AND / OR B-AMYLOID PEPTIDE
US9567198P 1998-08-07 1998-08-07
PCT/FR1998/002278 WO1999021886A1 (en) 1997-10-24 1998-10-23 PEPTIDES CAPABLE OF INHIBITING THE INTERACTION BETWEEN PRESENILINS AND THE β-AMYLOID PEPTIDE OR ITS PRECURSOR

Publications (3)

Publication Number Publication Date
NO20002001D0 true NO20002001D0 (en) 2000-04-17
NO20002001L NO20002001L (en) 2000-04-17
NO328908B1 NO328908B1 (en) 2010-06-14

Family

ID=26233891

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002001A NO328908B1 (en) 1997-10-24 2000-04-17 In vitro use of a polypeptide capable of inhibiting the interaction between presenilines and APP.

Country Status (13)

Country Link
EP (1) EP1025121B1 (en)
JP (1) JP2001521043A (en)
KR (1) KR100626475B1 (en)
CN (1) CN100429230C (en)
AU (1) AU766522B2 (en)
BR (1) BR9813105A (en)
CA (1) CA2305816C (en)
CY (1) CY1112236T1 (en)
CZ (1) CZ303226B6 (en)
HU (1) HU227660B1 (en)
IL (2) IL135751A0 (en)
NO (1) NO328908B1 (en)
WO (1) WO1999021886A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1025121B1 (en) * 1997-10-24 2011-08-24 Aventis Pharma S.A. Peptides capable of inhibiting the interaction between presenilins and the beta-amyloid peptide or its precursor
DE19909357A1 (en) * 1999-03-03 2000-09-07 Gerd Multhaup Copper agonist that binds to the APP copper binding site and / or has an inhibitory effect on the release of the amyloid-Aß peptide
WO2001062787A1 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Limited Diagnosis and treatment of bipolar affective disorder
EP1385880A2 (en) * 2001-03-16 2004-02-04 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Use of binding domains of presenilins for drug screening
WO2007092861A2 (en) * 2006-02-06 2007-08-16 Elan Pharmaceuticals, Inc. Inhibitors specific of presenilin-1 and their uses
WO2007123680A2 (en) * 2006-03-31 2007-11-01 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory
US8129334B2 (en) * 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
ES2530141B1 (en) * 2013-08-26 2016-01-15 Juan Carlos GALLAR RUIZ Peptide useful as a pharmacological target for the screening of molecules for the treatment and / or prevention of Alzheimer's disease, antibody against it and use of the antibody for the treatment and / or prevention of said disease.
CN108860921B (en) 2018-08-08 2020-11-20 上海鸿研物流技术有限公司 collapsible container

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2101774C (en) * 1991-01-21 2011-01-04 John A. Hardy Test and model for alzheimer's disease
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
JP2000506375A (en) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ Nucleic acids and proteins associated with Alzheimer's disease and uses thereof
EP1025121B1 (en) * 1997-10-24 2011-08-24 Aventis Pharma S.A. Peptides capable of inhibiting the interaction between presenilins and the beta-amyloid peptide or its precursor

Also Published As

Publication number Publication date
CZ20001462A3 (en) 2000-10-11
AU3129500A (en) 2000-12-14
BR9813105A (en) 2000-08-15
EP1025121B1 (en) 2011-08-24
HUP0004605A3 (en) 2002-09-30
CN1277616A (en) 2000-12-20
CA2305816C (en) 2012-07-10
IL135751A (en) 2010-12-30
CZ303226B6 (en) 2012-06-06
HU227660B1 (en) 2011-10-28
CA2305816A1 (en) 1999-05-06
KR20010024541A (en) 2001-03-26
WO1999021886A1 (en) 1999-05-06
JP2001521043A (en) 2001-11-06
NO328908B1 (en) 2010-06-14
AU766522B2 (en) 2003-10-16
IL135751A0 (en) 2001-05-20
NO20002001L (en) 2000-04-17
CN100429230C (en) 2008-10-29
HUP0004605A1 (en) 2001-04-28
KR100626475B1 (en) 2006-09-20
CY1112236T1 (en) 2015-12-09
EP1025121A1 (en) 2000-08-09

Similar Documents

Publication Publication Date Title
ATE237348T1 (en) LIQUID DRUGS CONTAINING GONADOTROPINS
DE69814235D1 (en) Condenser with multi-stage separation of the gas and liquid phases
DE4393381T1 (en) Peptides
DK0833649T4 (en) Protein hydrolyzate preparations for the prevention or treatment of allergies
BR9607318A (en) Peptides and pharmaceutical composition
ID23151A (en) PREPARAT MEDICINE THAT CONTAINS NOBLE LIPOFILIC GAS
DK6893D0 (en) PEPTIDE
ID24520A (en) ANALOGUE ANALOGES OF LH-RH PEPTIDES, THE USE AND THE PHARMACY COMPOSITION OF YAMG CONTAINS IT
EP1021202A4 (en) IMMUNOGENIC PEPTIDES FROM THE HPV E7 PROTEIN
NO995500D0 (en) Use of a pharmaceutical composition for the treatment of / or prevention of ischemia
NO985680D0 (en) peptide
EE9800453A (en) Nasal administration of desmopressin
LV10962A (en) New peptide
DK0839153T3 (en) Process for the preparation of peptides and N-carbamoyl protected peptides
DE69705628D1 (en) Chlorofluorocarbon free aerosol medicinal preparations containing MOMETASONFUROAT
NO20002001D0 (en) Peptides capable of inhibiting the interaction between presenilines and the &lt;beta&gt; -amyloid peptide or its precursor
IT1283772B1 (en) PROCEDURE FOR THE REINA AND DIACEREIN PREPARATION
DK1047445T3 (en) MODIFIED ENZYMES AND ITS APPLICATION FOR PEPTIDE SYNTHESIS
NO20000575D0 (en) Recombinant expression of insulin C peptide
DK1222921T3 (en) Pharmaceutical compositions containing tizoxanide and / or nitazoxanide
HUP0004535A3 (en) Roof cladding element, system and use of the elements
BR9709406B1 (en) substituted alkyloxyamino fluorenones and pharmaceutical composition containing them.
DE69427363D1 (en) Platelet-inhibiting peptides
ID21131A (en) COMPRESSOR OF TYPE SLOPE THRUST
DE69720266D1 (en) VERSATILE BRANCHED PEPTIDE CONSTRUCTIONS

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees